SCHEMBL20347151

SCHEMBL20347151

CC(C)(C)OC(Cc1cccc(N)c1)(C(=O)O)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.42
MAOA P21397 2/20 0.42
GRM2 Q14416 1/20 0.42
GRM3 Q14832 1/20 0.42
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 1/20 0.39
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
EGFR P00533 1/20 0.38
FYN P06241 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20347152 0.85 CTBP2 (0.43) MAOBGRM2GRM3THRATHRB
SCHEMBL19961863 0.84 SMN1; SMN2 (0.48) CYP1A2CYP2C19ALDH1A1CYP3A4RECQL
SCHEMBL26973347 0.84 PKM (0.47) MAOBMAOAGRM2GRM3APEX1
SCHEMBL24983272 0.82 CYP1A2 (0.49) GRM2GRM3CYP1A2MEN1ALDH1A1
SCHEMBL20350604 0.81 NR4A2 (0.47) MAOBMEN1MAPTKMT2APPARG
SCHEMBL20347160 0.81 CETP (0.46) KDM4EALDH1A1GAAHSD17B10TDP1
SCHEMBL20347416 0.81 BLM (0.45) MAOBMAOACYP1A2CYP2C19KDM4E
SCHEMBL20333946 0.81 GRM2 (0.41) MAOBMAOAGRM2GRM3CYP1A2
SCHEMBL21602286 0.79 PPARG (0.47) PPARGPPARA
SCHEMBL20347180 0.79 KMT2A (0.43) MEN1ALDH1A1FYNMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11034715-B2 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. (US) 2021-06-15 US disclosed
US-20200223882-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof ANTENGENE THERAPEUTICS LIMITED (CN) 2020-07-16 US disclosed
US-20180186827-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof ANTENGENE THERAPEUTICS LIMITED (CN) 2018-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186827-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof NT5E, ENTPD5, NT5C2 MAOB 96/4885MAOA 97/4885GRM2 1647/4885
US-20200223882-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof NT5E, ENTPD5, NT5C2 MAOB 96/4885MAOA 97/4885GRM2 1647/4885
US-11034715-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 MAOB 96/4885MAOA 97/4885GRM2 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.